Abstract:The study by Wagner et al. (https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1416319/full) employs advanced imaging techniques to visualize clot structures in extracorporeal membrane oxygenation (ECMO) devices, revealing the importance of platelet-leukocyte aggregates and von Willebrand factor in clot stability and dissolution. This work underscores the dynamic nature of thrombus formation, where mechanical forces and cellular components interact to influence clot architecture and stability. Similarly, the research by Yuan et al. (https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2023.1165589/full) delves into the role of Toll-like receptor 4 (TLR4) in thrombus resolution, highlighting the receptor's involvement in mediating inflammatory responses necessary for thrombus breakdown. In recent years, extensive research has explored the link between inflammation and thrombosis, revealing that the immune and coagulation systems are functionally interconnected (5). The study demonstrates that TLR4 deficiency impairs thrombus resolution in a mouse model, emphasizing the importance of inflammation and immune signaling in the clearance of thrombi. This finding aligns with the broader understanding that thrombosis is not merely a hemostatic event but also an inflammatory process, where immune cells and cytokines play pivotal roles (6)(7)(8)(9).A review by Khattak et al.(https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2024.1287553/full) further underscores the complex role of platelets in microvascular thrombosis during ST-elevation myocardial infarction (STEMI). The authors discuss how platelets, beyond their hemostatic function, contribute to inflammatory processes and microvascular obstruction, complicating recovery after myocardial infarction. Despite the widespread use of dual antiplatelet therapy, its effect on microvascular thrombosis remains unclear, driving the need for novel therapies targeting specific platelet receptors such as GPVI and PAR4. These emerging treatments show promise in mitigating microvascular damage with a lower risk of bleeding complications, offering new avenues for enhancing therapeutic strategies in STEMI management.The interplay between coagulation, inflammation and oxidative stress is further explored in the review by Bettiol et al.(https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2023.1325002/full), which examines the regulatory role of SIRT1 in thrombosis. SIRT1, a NAD+-dependent deacetylase, modulates key processes such as endothelial activation, platelet aggregation, and inflammatory response, thereby influencing thrombus formation and stability. This review puts SIRT1 as a potential therapeutic target, suggesting that modulating its activity could offer new avenues for preventing and treating thrombotic diseases.While these studies focus on the molecular and cellular underpinnings of thrombosis, other contributions in this collection address the clinical implications of these mechanisms. Wu et al.'s multicenter retrospective cohort study (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1373635/full) evaluates the efficacy and safety of direct oral anticoagulants (DOACs) compared to low-molecularweight heparin (LMWH) in preventing venous thromboembolism in hospitalized cancer patients. The results suggest that DOACs may offer a safer and more effective alternative to traditional therapies, highlighting the need for personalized treatment approaches based on a deeper understanding of the patient's thrombotic risk profile and the molecular characteristics of their condition.Moreover, the impact of novel therapeutic strategies on thrombosis is exemplified in the study by Rodenas et al.(https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2023.1182925/full), which investigates the use of venetoclax, a potent hepsin inhibitor, to reduce the metastatic and prothrombotic phenotypes of colorectal cancer cells. This research bridges the gap between oncology and thrombosis (10), demonstrating how targeted therapies can simultaneously address tumor progression and thrombotic risk, reflecting the interconnected nature of these pathophysiological processes.Collectively, the articles published in this Research Topic highlight the complexity of thrombosis as a multifaceted process involving hemostatic, inflammatory, and immune mechanisms. They also emphasize the potential of targeted therapies that go beyond traditional anticoagulation to modulate specific molecular pathways involved in thrombosis. As our knowledge of the molecular mechanisms underlying thrombosis advances, these studies offer a critical foundation for developing more targeted and effective therapeutic strategies, which will ultimately enhance patient outcomes and alleviate the public health burden of thr -Abstract Truncated-

Reflections on World Thrombosis Day 2024

A Happy New Year 2024 from Thrombosis and Haemostasis!

Welcome to Seminars in Thrombosis & Hemostasis 2023

Thrombosis and Haemostasis 2023 Editors' Choice Papers

Welcome to Seminars in Thrombosis and Hemostasis 2024: 50 Years of Publishing

Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis

Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part IV

Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress

Greats in the History of Thrombosis and Hemostasis

Current Topics from the Revised German S2k Guideline on Diagnosis and Treatment of Venous Thromboembolism

Editorial: Molecular mechanisms of thrombosis

Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress

New Seminars in Thrombosis and Hemostasis 2022 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

Laboratory Diagnostics for Thrombosis and Hemostasis Testing—Part 3

The Most Highly Cited Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 50 Years in the Making

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

Erratum to 'Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress' [Research and Practice in Thrombosis and Haemostasis Volume 8, Issue 4, May 2024, 102432]

Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum

Development of a Coagulation Disorders Unit

[The best of thrombosis in 2005]

Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis